ClinicalTrials.gg

Program

Bupropion

Also written as “bupropion hydrochloride”, “Extended-release Bupropion Hydrochloride” and “Extended-release bupropion hydrochloride”.

Its studies are mostly in Smoking Cessation · Depressive Disorder, Major · Depressive Disorder · Seasonal Affective Disorder · Obesity, led by 6 companies.

Furthest: phase 4, since Sep 24, 200219 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline80 open or runningphase 3since Sep 24, 2002Sep 24, 2002none ahead
Teva Pharmaceutical Industries60 open or runningphase 1since Mar 17, 2009Mar 17, 2009none ahead
Rose Research Center20 open or runningphase 3since May 11, 2020May 11, 2020none ahead
Johnson & Johnson10 open or runningphase 1since Oct 2, 2015Oct 2, 2015none ahead
Novartis10 open or runningphase 1since Apr 16, 2009Apr 16, 2009none ahead
Takeda10 open or runningphase 4since Nov 24, 2015Nov 24, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 24, 2002First study: phase 3 study in Seasonal Affective DisorderNew to GlaxoSmithKlineGlaxoSmithKline · NCT00046241 · 300 enrolled · United States, Canada
  2. Oct 30, 2002Phase 3 study in Attention Deficit Disorder with HyperactivityGlaxoSmithKline · NCT00048360 · 162 enrolled · United States
  3. Jan 7, 20032 phase 3 studies in Depressive Disorder, MajorGlaxoSmithKline · NCT00051272, NCT00051259
  4. Sep 25, 2003Phase 1 study in Depressive DisorderGlaxoSmithKline · NCT00069459 · 250 enrolled · United States
  5. Oct 5, 2004Phase 3 study in Depressive Disorder, MajorGlaxoSmithKline · NCT00093288 · 364 enrolled · Australia, Belgium, Finland and more
  6. Aug 24, 2005Phase 2 study in Depressive DisorderGlaxoSmithKline · NCT00135512 · 234 enrolled · Japan
  7. Mar 17, 2009Teva Pharmaceutical Industries's first studies: 5 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00865462, NCT00865410, NCT00865371 and 2 more
  8. Apr 16, 2009Novartis's first study: phase 1 study in HealthyNew to NovartisNovartis · NCT00883155 · 36 enrolled
  9. Jan 8, 2010Phase 1 study in Depressive DisorderTeva Pharmaceutical Industries · NCT01046214 · 8 enrolled · United States
  10. Jul 14, 2014Phase 3 study in Depressive Disorder, MajorGlaxoSmithKline · NCT02191397 · 534 enrolled · China
  11. Oct 2, 2015Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT02568176 · 71 enrolled · Belgium
  12. Nov 24, 2015Takeda's first study: phase 4 study in Weight Regain Post Bariatric SurgeryNew to TakedaTakeda · NCT02616315 · United States
  13. May 11, 2020Rose Research Center's first study: phase 3 study in Smoking CessationNew to Rose Research CenterRose Research Center · NCT04388319 · 26 enrolled · United States
  14. Oct 27, 2021Phase 3 study in Smoking CessationRose Research Center · NCT05205811 · 180 enrolled · United States

TargetBeta

“Dopamine transporter inhibitor; Dopamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
lisdexamfetamineruleTakedaphase 447
dexmethylphenidaterulecingulate-therapeuticsphase 414
AmphetamineruleTris Pharmaphase 48

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05205811Smoking Cessation · United States3CompletedRose Research CenterJun 19, 2025180
NCT04388319Smoking Cessation · United States3CompletedRose Research CenterJun 4, 202126
NCT02616315Weight Regain Post Bariatric Surgery · United States4WithdrawnTakedaOct 20170
NCT02568176Healthy · Belgium1CompletedJohnson & JohnsonFeb 201671
NCT02191397Depressive Disorder, Major · China3CompletedGlaxoSmithKlineOct 10, 2016534
NCT01046214Depressive Disorder · United States1TerminatedTeva Pharmaceutical Industries8
NCT00883155Healthy1CompletedNovartisOct 199836
NCT00865462Healthy · United States1CompletedTeva Pharmaceutical IndustriesJul 200430
NCT00865410Healthy · United States1CompletedTeva Pharmaceutical IndustriesSep 200426
NCT00865371Healthy · United States1CompletedTeva Pharmaceutical IndustriesSep 200426
NCT00865111Healthy · United States1CompletedTeva Pharmaceutical IndustriesApr 200626
NCT00863941Healthy · United States1CompletedTeva Pharmaceutical IndustriesJul 200428
NCT00135512Depressive Disorder · Japan2CompletedGlaxoSmithKlineMay 28, 2007234
NCT00093288Depressive Disorder, Major · Australia, Belgium, Finland and more3CompletedGlaxoSmithKlineOct 2005364
NCT00069459Depressive Disorder · United States1CompletedGlaxoSmithKlineJun 3, 2004250
NCT00051272Depressive Disorder, Major · United States3CompletedGlaxoSmithKlineJun 2004425
NCT00051259Depressive Disorder, Major · United States3CompletedGlaxoSmithKlineJun 2004420
NCT00048360Attention Deficit Disorder with Hyperactivity · United States3CompletedGlaxoSmithKlineJun 2003162
NCT00046241Seasonal Affective Disorder · United States, Canada3CompletedGlaxoSmithKlineJun 2003300

How it is read

Names in the registry

  • “Bupropion”, 7 entries
  • “bupropion hydrochloride”, 3 entries
  • “Extended-release Bupropion Hydrochloride”, 2 entries
  • “Extended-release bupropion hydrochloride”, 2 entries
  • “Bupropion HCl”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.